Bronchogen

Bronchogen is a short synthetic peptide from the Russian 'Khavinson' bioregulator family, marketed for the bronchi and lungs. The idea behind these peptides is that a very short amino-acid sequence can bind DNA and nudge gene activity in its matching organ, in this case lung tissue. The research on Bronchogen is Russian, preclinical (cell and DNA-binding studies, not human trials), hasn't been independently replicated in the West, and it isn't approved as a medicine or FDA-approved.

Bronchogen is marketed as a lung "bioregulator," but the published evidence is preclinical. Lab studies report that the peptide binds DNA and shows sequence-preferential binding to certain DNA motifs, supporting a broad theory that short peptides can influence gene activity. These are laboratory findings — there are no large controlled human trials showing Bronchogen improves any lung condition.

Not a drug in the US and not FDA-approved for any indication. A synthetic "Khavinson" short-peptide bioregulator ("cytogen") developed at the St. Petersburg Institute of Bioregulation and Gerontology (Russia), associated with bronchial/lung tissue. Evidence is almost entirely preclinical (cell, DNA-binding, and animal work) plus small Russian studies; there are no large controlled human trials. WADA: not specifically named on the Prohibited List; as a non-approved research peptide it is best treated as captured under S0 (non-approved substances), prohibited at all times — verify with your anti-doping organization. Not DEA-scheduled.

Bronchogen has essentially no human safety data from controlled trials. It is not FDA-approved and is not a treatment for any lung condition. As a non-approved research peptide it is best treated as prohibited in regulated sport (WADA S0). Anyone with a respiratory condition should see a clinician rather than rely on an unproven peptide. VialWise is a research and educational reference, not medical advice.

⚠️ For research and educational purposes only. Bronchogen is not FDA-approved and is not a treatment for asthma, COPD, or any lung condition. Its evidence is preclinical. Information here is informational, not medical advice.

⚠️ Part of the Khavinson "bioregulator" family — read the shared caveat. Bronchogen is one of a set of short peptides from the St. Petersburg Institute of Bioregulation and Gerontology, each tied to an organ. The whole family shares a thin, mostly-preclinical, largely single-institute evidence base and no large controlled human trials.[³] Treat the tissue-specific claims as a research theory, not established medicine.

Bronchogen is a synthetic tetrapeptide, Ala-Glu-Asp-Leu (AEDL), and one of the "Khavinson" short-peptide bioregulators — a family developed at the St. Petersburg Institute of Bioregulation and Gerontology (see the shared framing below). Within that family, Bronchogen is the peptide associated with bronchial/lung tissue.

Mechanism (as proposed and studied preclinically). According to PubMed, Bronchogen's sequence (Ala-Glu-Asp-Leu) has been confirmed and studied for direct interaction with DNA: in a differential-scanning-calorimetry study it acted as a DNA-stabilizing agent, raising DNA melting temperature at specific peptide/DNA ratios,[¹] and in a separate fluorescence study it showed sequence-preferential binding (preferring CTG-containing motifs).[²] These findings are cited by the Khavinson group as support for the broader idea that short peptides can reach the cell nucleus and epigenetically influence gene activity in their target tissue.[²][³]

Evidence quality. Preclinical. The Bronchogen-specific data are biophysical/cell-level (DNA binding), not clinical. There are no large controlled human trials demonstrating a lung benefit. Like the rest of this family, the evidence is thin and concentrated in a single research tradition.

### About the Khavinson bioregulators (shared framing)

The "bioregulator" or cytomedin/cytogen peptides were developed from the 1970s onward by Vladimir Khavinson and colleagues at the St. Petersburg (Leningrad) Institute of Bioregulation and Gerontology. The original preparations ("cytomedins") were peptide complexes extracted from animal organs; the newer "cytogens" are synthetic short peptides (di- to tetrapeptides) designed from those extracts, each proposed to have tissue-specific activity on the organ it came from.[¹ umbrella review][³] The group's "peptide theory of ageing" holds that aging involves declining tissue-specific peptide signaling and that supplying these short peptides can normalize gene expression in the corresponding organ.[³]

The honest caveats for the whole family: the evidence base is overwhelmingly preclinical (explant cultures, cell studies, DNA-binding assays, animal work) plus small, often non-blinded, largely Russian-language clinical reports; there are no large, independent, randomized controlled trials; none are FDA-approved; and the compounds are marketed in Russia as injectables and oral supplements. They should be understood as an interesting but unproven research tradition.

Regulatory status (US). Not FDA-approved; not a drug. Not DEA-scheduled. Available only as research-supply material or imported supplement outside the FDA-recognized supply chain.

Regulatory status (sport — WADA). Not specifically named on the Prohibited List; as a non-approved research peptide, best treated as S0 (non-approved substances), prohibited at all times. Verify with your anti-doping organization.

Common research interests. Bronchial/lung support (its associated organ). This is an extrapolation from the tissue-specific theory and preclinical data — not an established human use.

Commonly reported

• Injection-site reactions (redness, soreness)
• Reactions to research-supply material of variable purity
• DNA-interacting activity. Bronchogen binds DNA in vitro;[¹][²] the long-term consequences of peptides that interact with DNA/gene expression in humans are not characterized.
• Unknown long-term safety — no long-term human data.

Not a treatment for any lung condition — see a clinician for respiratory disease

Pregnancy and lactation — no data; default to contraindicated

Pediatric use — no data; not for researchers under 18

Active malignancy — caution; effects of DNA/gene-activity-modulating peptides in the cancer context are uncharacterized

Known hypersensitivity — contraindicated

Regulatory note (US): Not FDA-approved; not DEA-scheduled.

Regulatory note (sport): Best treated as WADA S0 (non-approved). Verify with your anti-doping organization.

Bioregulator (Khavinson peptide)

A very short synthetic peptide from the St. Petersburg Institute of Bioregulation and Gerontology, each associated with one organ and proposed to influence that tissue's gene activity.

Cytogen

The name for the synthetic short-peptide versions of these bioregulators (as opposed to the older tissue-extract "cytomedin" preparations).

Preclinical

Research in cells or animals, before human testing. Most bioregulator evidence is preclinical and from one research group.

Tissue-specific

The claim that each peptide mainly affects its matching organ — here, the bronchi/lungs.

1. Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. (2011). Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bulletin of Experimental Biology and Medicine, 150(3):375–377.(PMID 21240358)
2. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow), 76(11):1210–1219.(PMID 22117547)
3. Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinology Letters, 23 Suppl 3:11–144.(PMID 12374906)

• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Chonluten — same mechanism class
• Cortagen — same mechanism class
• Crystagen — same mechanism class
• Epitalon — same mechanism class